Cambridge, United Kingdom, January 26, 2026 — Scancell Holdings plc announced on January 26, 2026, that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a registrational Phase 3 clinical trial of iSCIB1+, its lead Immunobody® cancer immunotherapy, in patients with advanced unresectable stage IIIB/IV melanoma. The FDA clearance enables Scancell to proceed with late-stage clinical development, positioning the company to begin a global Phase 3 trial in 2026, with progression-free survival (PFS) agreed as the primary surrogate endpoint for regulatory evaluation.
Science Significance
iSCIB1+ is a DNA Immunobody® immunotherapy designed to stimulate a potent, tumor-specific T-cell immune response against melanoma-associated antigens. Unlike passive antibody therapies, iSCIB1+ actively trains the immune system to recognize and destroy cancer cells, aiming to generate long-lasting anti-tumor immunity. In the Phase 2 SCOPE trial, patients treated with iSCIB1+ demonstrated a 74% progression-free survival rate at 16 months in the target population, significantly outperforming historical benchmarks from standard-of-care checkpoint inhibitor regimens. This compares favorably with reported PFS rates of approximately 50% at 11.5 months in patients receiving ipilimumab plus nivolumab alone. The therapy also showed consistent benefit across difficult-to-treat subgroups, including PD-L1–low tumors, BRAF wild-type disease, and patients previously exposed to checkpoint inhibitors, reinforcing its scientific potential to redefine melanoma treatment outcomes.
Regulatory Significance
The FDA’s IND clearance represents a critical regulatory milestone, validating the safety, manufacturing quality, and clinical rationale supporting Scancell’s Phase 3 development program. The Phase 3 trial is intended to serve as a registrational study, potentially forming the basis of a future Biologics License Application (BLA) or marketing authorization if results confirm efficacy and safety. Regulatory endorsement of progression-free survival as a surrogate endpoint reflects confidence in the therapy’s clinical relevance and supports an accelerated pathway toward potential approval. Scancell also indicated ongoing engagement with global regulatory agencies to ensure alignment on trial design, manufacturing standards and long-term commercialization strategy.
Advertisement
Business Significance
From a commercial standpoint, FDA IND clearance positions Scancell to advance a first-in-class active immunotherapy in a highly competitive oncology market. Melanoma remains a significant global cancer burden despite advances in checkpoint inhibition, and therapies capable of improving durability and response rates represent meaningful market opportunities. The IND milestone strengthens Scancell’s corporate valuation, enhances its partnership and licensing prospects, and supports continued fundraising or strategic collaborations to finance Phase 3 development. The company noted that it continues to evaluate financing options and partnering discussions to support trial execution and long-term growth of its immunotherapy pipeline.
Patients’ Significance
For patients with advanced melanoma, treatment resistance and disease progression remain major challenges even with current immunotherapy regimens. iSCIB1+ offers the potential to extend progression-free survival, improve durability of response, and enhance long-term disease control through immune system activation. Patients who historically experience limited benefit from checkpoint inhibitors — including those with low PD-L1 expression or prior treatment exposure — may particularly benefit from this novel immunotherapeutic approach. If successful in Phase 3, iSCIB1+ could represent a new standard-of-care option for melanoma patients seeking more durable and effective treatment outcomes.
Policy Significance
The advancement of iSCIB1+ aligns with broader public-health and oncology policy priorities aimed at accelerating innovation in cancer immunotherapy, improving survival in metastatic cancers, and expanding access to transformative treatment options. Regulatory support for late-stage trials of active immunotherapies reinforces policy efforts to modernize oncology drug development and encourage precision-medicine approaches tailored to patient genetics. Scancell’s use of biomarker-based patient selection also reflects evolving policy trends favoring personalized cancer treatment strategies.
Scancell’s FDA IND clearance for its Phase 3 iSCIB1+ melanoma trial marks a major step forward in the development of active cancer immunotherapy. With strong Phase 2 efficacy signals, a genetically guided patient-selection strategy and regulatory alignment on trial endpoints, the company is positioned to advance a potentially practice-changing melanoma treatment. As Phase 3 development begins in 2026, iSCIB1+ stands as a promising candidate to improve long-term outcomes for patients facing advanced melanoma.
Source: Scancell Holdings plc press release
